Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Research

• Publication date

  2004-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-04-1945PMID 15574759
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overexpression of the amplified Pip4k2β gene from 17q11–12 in breast cancer cells confers proliferation advantage

  2004cited by this paper
• KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.

  2004cited by this paper
• C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

  2003cited by this paper
• Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.

  2003cited by this paper
• Tissue microarrays in drug discovery

  2003influential reference
• Expert Commentary.

  2002cited by this paper
• HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.

  2002cited by this paper
• HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer

  2002cited by this paper
• Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

  2002cited by this paper
• Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

  2002cited by this paper
• Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.

  2002cited by this paper
• Amplification of c-myc by Fluorescence In Situ Hybridization in a Population-Based Breast Cancer Tissue Array

  2001cited by this paper
• Immunohistochemical study of c-erbB-2 expression in primary breast cancer.

  2001cited by this paper
• Evaluating HER2 amplification and overexpression in breast cancer

  2001cited by this paper
• Tissue microarrays for rapid linking of molecular changes to clinical endpoints.

  2001cited by this paper
• Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.

  2000cited by this paper
• Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations.

  2000influential reference
• Online access to CGH data of DNA sequence copy number changes.

  2000cited by this paper
• C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance

  2000cited by this paper
• Medullary carcinoma of the breast and BRCA1 mutation

  2000cited by this paper
• Pathological prognostic factors in breast cancer.

  1999cited by this paper
• Characterization of topoisomerase IIα gene amplification and deletion in breast cancer

  1999cited by this paper
• Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis

  1999cited by this paper
• Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.

  1999cited by this paper
• High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays

  1998cited by this paper
• CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei

  1998cited by this paper
• The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

  1998cited by this paper
• AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.

  1997cited by this paper
• Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.

  1997influential reference
• EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer

  1997cited by this paper
• Matrix‐based comparative genomic hybridization: Biochips to screen for genomic imbalances

  1997cited by this paper
• Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.

  1997cited by this paper
• Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization

  1997cited by this paper
• Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors

  1996cited by this paper
• DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours.

  1996cited by this paper
• Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.

  1996cited by this paper
• Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

  1995cited by this paper
• mdm2 gene alterations and mdm2 protein expression in breast carcinomas

  1995influential reference
• Typical medullary carcinoma of the breast: A clinical and pathological analysis of 52 cases

  1995cited by this paper
• Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status.

  1995cited by this paper
• ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin‐embedded breast carcinoma tissues

  1995cited by this paper
• Prognostic association of c-erbB-2 oncogene amplification and protein overexpression in human breast cancer using archival tissues. A comparative study.

  1994cited by this paper
• Molecular cytogenetics of human breast cancer.

  1994cited by this paper
• Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.

  1994cited by this paper
• Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations

  1994cited by this paper
• Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.

  1993cited by this paper
• p53 Mutations and Histologie Type of Invasive Breast Carcinoma

  1993cited by this paper
• c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse.

  1992cited by this paper
• c‐myc amplification is an independent prognostic factor in postmenopausal breast cancer

  1992cited by this paper
• Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.

  1992cited by this paper
• ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.

  1992cited by this paper
• c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.

  1992cited by this paper
• pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

  1991cited by this paper
• Epidermal growth factor receptors and prognosis in primary breast cancer

  1990cited by this paper
• Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.

  1989cited by this paper
• Amplification of c‐myc and c‐erbB‐2 proto‐oncogenes in human solid tumors: Frequency and clinical significance

  1989cited by this paper
• c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.

  1989cited by this paper
• Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma.

  1988cited by this paper
• Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

  1985cited by this paper

• Molecular insights into anti-cancer cyclotides and their interaction with breast cancer targets: an in silico study.

  2026cites this paper
• Protein Nanocarriers: Targeted Theranostics for Cancer Treatment and Imaging

  2026cites this paper
• C‐Myc Overexpression in Adolescent and Young Adult Breast Cancer: Distinct From Older Adults With Relevantly Expressed Cholecystokinin B Receptor

  2025cites this paper
• Design and Synthesis of 2-substituted phenyl-4,5-diphenyl imidazole linked benzotriazoles: Anti-breast cancer activity, cell cycle analysis, apoptosis assay, and in silico studies

  2025cites this paper
• EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

  2025cites this paper
• Design, synthesis, anti-breast cancer and in silico studies of substituted triphenyl imidazole-N-alkyl linked indole derivatives.

  2025cites this paper
• Discovery of Airway-Administered Ionophores for Mn2+ to Mitigate Lung Metastasis by Targeting Disseminated Tumor Cell.

  2025cites this paper
• Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition

  2025cites this paper
• Enhancer regulatory networks globally connect non-coding breast cancer loci to cancer genes

  2025cites this paper
• Discovery of novel natural product-derived EGFR inhibitors using multiple linear regression, stacked ensemble regression, and fingerprinting approaches

  2025cites this paper
• EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

  2025cites this paper
• Impact of CCND1 amplification on the prognosis of hormone receptor–positive, HER2-negative breast cancer patients—correlation of clinical and pathological markers

  2024cites this paper
• Machine learning in breast cancer imaging: a review on data, models and methods

  2024cites this paper
• Lapatinib-induced enhancement of mitochondrial respiration in HER2-positive SK-BR-3 cells: mechanism revealed by analysis of proteomic but not transcriptomic data

  2024cites this paper
• HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice

  2024cites this paper
• Advancements in computer vision and pathology: Unraveling the potential of artificial intelligence for precision diagnosis and beyond.

  2024cites this paper
• Single-Sample Networks Reveal Intra-Cytoband Co-Expression Hotspots in Breast Cancer Subtypes

  2024cites this paper
• NDRGs in Breast Cancer: A Review and In Silico Analysis

  2024cites this paper
• Enhancer regulatory networks globally connect non-coding breast cancer loci to cancer genes

  2023cites this paper
• The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma

  2023cites this paper
• Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications

  2023cites this paper
• Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity

  2022cites this paper
• Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer

  2022cites this paper
• High PPFIA1 expression promotes cancer survival by suppressing CD8+ T cells in breast cancer: drug discovery and machine learning approach

  2022cites this paper
• Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

  2022cites this paper
• Characteristics of MYC Amplification and Their Association with Clinicopathological and Molecular Factors in Patients with Breast Cancer

  2022cites this paper
• Antitumorigenic Effect of Tramadol and Synergistic Effect With Doxorubicin in Human Breast Cancer Cells

  2022cites this paper
• IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target

  2022cites this paper
• Estimation of Interleukin‐10 and Interleukin‐22 Levels in the Advances of Breast Cancer

  2022cites this paper
• A molecular reappraisal of matrix-producing breast metaplastic carcinoma highlighted by PLAG1 and MYC rearrangements

  2022cites this paper
• NDRG1 in Cancer: A Suppressor, Promoter, or Both?

  2022cites this paper
• Prognostic and Predictive Value of CCND1/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis

  2022cites this paper
• Non-canonical approaches to targeting hypoxic tumors.

  2022cites this paper
• High mitochondrial content is associated with breast cancer aggressiveness

  2021cites this paper
• ErbB4‐mediated regulation of vasculogenic mimicry capability in breast cancer cells

  2021cites this paper
• MYC amplifications are common events in childhood osteosarcoma

  2021cites this paper
• Expression profile of tumour suppressor protein p53 and its regulator MDM2 in a cohort of breast cancer patients in a Tertiary Hospital in Ghana

  2021cites this paper
• A review of the endocrine resistance in hormone-positive breast cancer.

  2021cites this paper
• Expression and Prognosis of HER Family in Breast Cancer

  2021cites this paper
• Y-chromosome loss is frequent in male renal tumors

  2021cites this paper
• Binding Potential of Dysidea Herbacea Derived Small Molecules to Breast Cancer Implicating Targets Estrogen and Epidermal Growth Factor Receptors

  2021cites this paper
• TCRM_A_251668 193..207

  2021cites this paper
• 6q deletion is frequent but unrelated to patient prognosis in breast cancer

  2021cites this paper
• Bioinformatics Study of Sea Cucumber Peptides as Antibreast Cancer Through Inhibiting the Activity of Overexpressed Protein (EGFR, PI3K, AKT1, and CDK4)

  2021cites this paper
• OTT_A_309091 3309..3318

  2021cites this paper
• Identification of Candidate Genes in Early-Stage Invasive Ductal Carcinoma Patients with High-Risk Mortality Using Genes Commonly Involved in Breast Cancer: A Retrospective Study

  2021cites this paper
• PTGS2 Over-Expression: A Colorectal Carcinoma Initiator not an Invasive Factor.

  2021cites this paper
• Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.

  2021cites this paper
• mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease

  2021cites this paper
• Comparison of the multigene panel test and OncoScan™ for the determination of HER2 amplification in breast cancer.

  2021cites this paper
• Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives

  2021cites this paper
• Decoupling Protein Production from Cell Growth Enhances the Site-Specific Incorporation of Noncanonical Amino Acids in E. coli.

  2020cites this paper
• Evaluation of HER2, MDM2, MYC, MET and TP53 gene copy number alterations in gastric cancer patients

  2020cites this paper
• Identi cation of Candidate Genes in Early-Stage Invasive Ductal Carcinoma Patients with High-Risk Mortality using 32 Genes Commonly Involved in Breast Cancer: A Retrospective Study

  2020cites this paper
• MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer

  2020cites this paper
• Prediction in Cancer Genomics Using Topological Signatures and Machine Learning

  2020cites this paper
• PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer

  2020cites this paper
• Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer

  2020cites this paper
• Tracking cells in epithelial acini by light sheet microscopy reveals proximity effects in breast cancer initiation

  2020cites this paper
• Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2

  2020cites this paper
• New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

  2020cites this paper
• Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study.

  2020cites this paper
• Cyclin D3-CDK6 Complex Facilitates Tumorigenesis by Regulating the C-Myc/miR-15a/16 Axis in a Feedback Loop in Gastric Cancer

  2020cites this paper
• بررسی تغییرات تعداد نسخه ژنهای HER2، MDM2، MYC، MET و TP53 در بیماران مبتلا به سرطان معده

  2020cites this paper
• Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer

  2019cites this paper
• Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort

  2019cites this paper
• High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer

  2019cites this paper
• Tracking the cells of tumor origin in breast organoids by light sheet microscopy

  2019cites this paper
• Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity.

  2019cites this paper
• The prognostic value of cyclin D1 expression in the survival of cancer patients: A meta-analysis.

  2019cites this paper
• c-Myc directly targets an over-expression of pyruvate carboxylase in highly invasive breast cancer.

  2019cites this paper
• Liprin-α1 in cancer cell adhesion machinery and tumor progression

  2019cites this paper
• OTT_A_214611 7749..7756

  2019cites this paper
• Liprin-β1 is upregulated in human hepatocellular carcinoma and is associated with advanced tumor stage

  2019cites this paper
• Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer

  2019cites this paper
• Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer

  2019cites this paper
• Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

  2019cites this paper
• microRNA as a systemic intervention in the specific breast cancer subtypes with C‐MYC impacts; introducing subtype‐based appraisal tool

  2018cites this paper
• Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.

  2018cites this paper
• Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer

  2018cites this paper
• A Novel Two-Stage Deep Method for Mitosis Detection in Breast Cancer Histology Images

  2018cites this paper
• Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer.

  2018cites this paper
• Immunohistochemical expression of anti-apoptotic protein bcl2 and its correlation with hormone receptors in breast cancers

  2018cites this paper
• Using Immunohistochemistry Without Linkers to Determine the Optimum Concentrations of Primary Antibodies for Immunofluorescence Staining of Formalin-fixed Paraffin-embedded Tissue Sections

  2018cites this paper
• Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma

  2017cites this paper
• Abstract P6-07-14: New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy

  2017cites this paper
• βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.

  2017cites this paper
• Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer

  2017influential citation
• PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse

  2017cites this paper
• The receptor tyrosine kinase Met and the protein tyrosine phosphatase PTPN 2 in breast cancer

  2017cites this paper
• Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells

  2017cites this paper
• Investigation of c-Myc gene amplification in breast cancer patients and its correlation with other prognostic factors

  2017cites this paper
• Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.

  2017cites this paper
• Investigated the chemotherapy and prognosis of invasive ductal carcinoma patients based on the different molecular phenotypes

  2017cites this paper
• MYC overexpression with its prognostic and clinicopathological significance in breast cancer

  2017cites this paper
• Clinicopathological and prognostic significance of cyclin D 1 amplification in patients with breast cancer : a meta-analysis

  2017cites this paper
• Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol

  2017cites this paper
• Clinicopathological and prognostic significance of cyclin D1 amplification in patients with breast cancer: a meta-analysis.

  2017cites this paper
• High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer

  2017cites this paper
• Mechanisms of Oncogene Activation

  2016cites this paper